ASTRAZENECA PLC

Form 6-K August 17, 2018
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For August 17, 2018
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82

EXPLANATORY NOTE

In connection with the issuance by AstraZeneca PLC of \$850,000,000 aggregate principal amount of 3.500% Notes due 2023, \$400,000,000 aggregate principal amount of Floating Rate Notes due 2023, \$1,000,000,000 aggregate principal amount of 4.000% Notes due 2029 and \$750,000,000 aggregate principal amount of 4.375% Notes due 2048 (collectively, the "Securities"), AstraZeneca PLC is filing the following documents solely for incorporation into the Registration Statement on Form F-3 (File No. 333-214756):

Exhibit List

Exhibit No.	Description
<u>1.1</u>	<u>Underwriting Agreement, dated as of August 14, 2018</u>
1.2	Pricing Agreement, dated as of August 14, 2018
	Officers' Certificate of the Registrant pursuant to Section 2.08 of the Indenture setting forth the terms of the
<u>4.1</u>	Securities, including forms of the global notes for the 3.500% Notes due 2023, the Floating Rate Notes due
	2023, the 4.000% Notes due 2029 and the 4.375% Notes due 2048.
<u>5.1</u>	Opinion of Freshfields Bruckhaus Deringer LLP
<u>5.2</u>	Opinion of Davis Polk & Wardwell London LLP

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ASTRAZENECA PLC

(Registrant)

Date: August 17, 2018 By:/s/ Adrian Kemp

Name: Adrian Kemp Title: Company Secretary